EUDA Health (EUDA) Holdings will launch EUDA Helixe 2.0 in January 2026, marking the next generation upgrade of its premium youthful vitality and longevity supplement. EUDA Helixe 2.0 introduces enhancements across formulation strength, ingredient technology, delivery systems, packaging design, and global market readiness. EUDA Helixe 2.0 features a 20% increase in New Zealand sourced deer placenta powder, with dosage enhanced from 100 mg to 120 mg, reinforcing the supplement’s positioning as a high potency vitality formulation. As part of the formulation upgrade, L-glutathione has been replaced with D-alpha-tocopherol. This change is designed to improve antioxidant stability, support cellular protection, enhance skin health and bolster overall youthful vitality, aligning EUDA Helixe 2.0 with long-term wellness and anti-aging objectives.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EUDA:
- EUDA Health Launches Stem Cell Platform and First Longevity Clinic in Shenzhen
- EUDA Health launches stem cell therapy platform, opens first clinic in Shenzhen
- EUDA Health Integrates QB Utility Token Into Digital Health and Rewards Platform
- EUDA Health to introduce QB utility token into health, rewards platform
- EUDA Health Cuts Warrant Exercise Price in December Funding Adjustment